This has even been demonstrated in hard-to-model ER+ breast cancer, in which phosphoinositide 3-kinase (PI3K) pathway activation and outgrowth of stem cell populations, have been found during acquired resistance to anti-oestrogen therapies (Cottu et al., 2014; Simões et al., 2015). The gene discussed is PIK3CA; the disease is breast carcinoma.